nateglinide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihyperglycaemics 1886 105816-04-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nateglinide
  • D-Nateglinide
  • glinate
  • glunate
  • natelide
  • senaglinide
A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES.
  • Molecular weight: 317.43
  • Formula: C19H27NO3
  • CLOGP: 4.30
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 2
  • TPSA: 66.40
  • ALOGS: -4.57
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.36 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.32 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 13 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 16.20 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 73 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.15 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.80 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.03 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 22, 2000 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 56.02 42.40 13 125 8394 2349553
Decreased appetite 48.52 42.40 15 123 28876 2329071

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 70.02 40.00 17 117 8421 1738226
Disease progression 44.87 40.00 14 120 17249 1729398

Pharmacologic Action:

SourceCodeDescription
ATC A10BX03 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Other blood glucose lowering drugs, excl. insulins
FDA EPC N0000175428 Glinide
FDA MoA N0000175448 Potassium Channel Antagonists
CHEBI has role CHEBI:35526 hypoglycemic agent
MeSH PA D007004 Hypoglycemic Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Infectious disease contraindication 40733004
Hypopituitarism contraindication 74728003 DOID:9406
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Primary adrenocortical insufficiency contraindication 373662000
Fever contraindication 386661006
Surgical procedure contraindication 387713003
Traumatic injury contraindication 417746004

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.79 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sulfonylurea receptor 1, Kir6.2 Ion channel BLOCKER Ki 6.46 WOMBAT-PK CHEMBL
Sulfonylurea receptor 2, Kir6.2 Ion channel BLOCKER Ki 4.99 WOMBAT-PK
Solute carrier family 22 member 6 Transporter Ki 5.04 CHEMBL

External reference:

IDSource
D000077715 MESH_DESCRIPTOR_UI
4021252 VUID
N0000148693 NUI
C0903898 UMLSCUI
D01111 KEGG_DRUG
41X3PWK4O2 UNII
7594 INN_ID
134604002 SNOMEDCT_US
d04743 MMSL
15875 MMSL
274332 RXNORM
4021252 VANDF
387070004 SNOMEDCT_US
167424 MMSL
009028 NDDF
CHEMBL783 ChEMBL_ID
CHEMBL249263 ChEMBL_ID
DB00731 DRUGBANK_ID
CHEBI:31897 CHEBI
5311309 PUBCHEM_CID
6833 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Starlix HUMAN PRESCRIPTION DRUG LABEL 1 0078-0351 TABLET 60 mg ORAL NDA 16 sections
Starlix HUMAN PRESCRIPTION DRUG LABEL 1 0078-0352 TABLET 120 mg ORAL NDA 16 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 0591-3354 TABLET 60 mg ORAL ANDA 16 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 0591-3355 TABLET 120 mg ORAL ANDA 16 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 0615-7585 TABLET, COATED 60 mg ORAL ANDA 11 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 0615-7586 TABLET, COATED 120 mg ORAL ANDA 11 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 42291-636 TABLET, COATED 60 mg ORAL ANDA 10 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 42291-637 TABLET, COATED 120 mg ORAL ANDA 10 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 49884-984 TABLET, COATED 60 mg ORAL ANDA 16 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 49884-985 TABLET, COATED 120 mg ORAL ANDA 16 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 52536-063 TABLET 60 mg ORAL ANDA 16 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 52536-067 TABLET 120 mg ORAL ANDA 16 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 54868-6255 TABLET, COATED 120 mg ORAL ANDA 10 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 55111-328 TABLET 60 mg ORAL ANDA 12 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 55111-329 TABLET 120 mg ORAL ANDA 12 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 60429-434 TABLET, COATED 60 mg ORAL ANDA 16 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 60429-435 TABLET, COATED 120 mg ORAL ANDA 16 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 68084-458 TABLET, COATED 60 mg ORAL ANDA 16 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 68084-459 TABLET, COATED 120 mg ORAL ANDA 16 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 68382-721 TABLET, FILM COATED 60 mg ORAL ANDA 17 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 68382-722 TABLET, FILM COATED 120 mg ORAL ANDA 17 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 70771-1015 TABLET, FILM COATED 60 mg ORAL ANDA 17 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 70771-1016 TABLET, FILM COATED 120 mg ORAL ANDA 17 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 71209-030 TABLET, COATED 60 mg ORAL ANDA 16 sections
Nateglinide HUMAN PRESCRIPTION DRUG LABEL 1 71209-031 TABLET, COATED 120 mg ORAL ANDA 16 sections
NATEGLINIDE HUMAN PRESCRIPTION DRUG LABEL 1 75834-205 TABLET, COATED 60 mg ORAL ANDA 17 sections
NATEGLINIDE HUMAN PRESCRIPTION DRUG LABEL 1 75834-206 TABLET, COATED 120 mg ORAL ANDA 17 sections